复方克林霉素搽剂治疗寻常痤疮

目的 :观察复方克林霉素搽剂治疗寻常痤疮的疗效。方法 :采用开放、多中心临床试验方法以复方克林霉素搽剂治疗 153例寻常痤疮病人 (男性53例 ,女性 10 0例 ,年龄 2 2a±s 6a) ,每日 3次涂于面部 ,连续 4wk ,每 2wk随访。结果 :复方克林霉素搽剂治疗寻常痤疮 ,4wk总显效率达 83.0 % ,对脓疱和丘疹的总有效率分别为 96.1%和 80 .7% ,不良反应率为 1.9%。结论 :复方克林霉素搽剂治疗痤疮疗效显著 ,安全性高 ,使用方便     

0．1％达芙文凝胶治疗122例寻常痤疮疗效观察

寻常痤疮是发生于毛囊皮脂腺的慢性炎症性皮肤病 ,对患者面部美观造成很大心理压力 ,患者求医心切。我科于 2 0 0 0年8月至 2 0 0 1年 4月应用法国高德美公司生产的达芙文 (0 .1%阿达帕林 )凝胶治疗寻常痤疮 ,对其疗效及安全性进行临床观察 ,并与本院自制的复方雷硫洗剂进行对照观察 ,现归纳总结如下。1　资料与方法1.1　临床分级 :我们按国际改良分类法 ,将寻常痤疮分为 ～ 级 : 级是以粉刺为主 ,少量丘疹和脓疱 ,总病灶数少于 30 ; 级有粉刺 ,并有中等量丘疹和脓疱 ,总病灶数在 31～ 5 0之间 ; 级有大量丘疹和脓疱 ,偶见大的炎性皮损 ,分…     

复方红氯酊治疗寻常型痤疮的疗效观察

目的:观察复方红氯酊治疗轻、中度寻常型痤疮的临床疗效.方法:轻、中度寻常型痤疮患者150例,随机分为两组.治疗组(75例)外用复方红氯酊,对照组外用林可霉素维B<,6>乳膏.治疗6周后比较两组皮损消退率、疗效及不良反应.结果:治疗组总有效率93.33%,明显高于对照组的69.33%(P<0.01);对炎性丘疹及脓疱的皮...     

复方奥硝唑搽剂治疗寻常痤疮临床观察

目的：评价复方奥硝唑搽剂治疗寻常痤疮的临床疗效。方法：将入选患者随机分为治疗组和对照纽，每组各61例。治疗组应用复方奥硝唑搽剂，对照组应用复方硫洗剂，在治疗2～4周后复查或随访，观察皮损情况并计算疗效指标，按疗效标准判定。结果：经治疗后治疗组和对照组有效率分别为88．52％、60．66％，两组比较有显著性差异（P〈0．05）。结论：复方奥硝唑搽剂治疗寻常痤疮的疗效显著，优于复方硫洗剂，且较安全，是一种理想外用治疗寻常痤疮的药物。     

LED红蓝光治疗痤疮145例临床疗效观察

目的观察红、蓝色LED光源治疗轻、中度炎性痤疮的疗效。方法采用波长415nm蓝色LED光源及波长633nm红光光源治疗轻、中度炎性痤疮145例,分别记录治疗前及治疗后1、4、8周丘疹和脓疱的数目变化,统计结果并进行疗效评价。结果使用LED红蓝光交替照射痤疮皮损,145例患者治疗前及1、4、8周丘疹、脓疱皮损及皮损减少率见表1,在疗程结束时,患者的炎性损害数目平均减少48.9%,治疗后第8周炎性损害的平均减少率72.0%,结论应用LED红蓝光光源交替照射,可以明显降低痤疮的炎性损害,且在治疗结束后炎性损害仍可继续减少,不良反应轻微,患者依从性好。     

红霉素醋酸锌凝胶和软膏治疗寻常型痤疮

目的：评价红霉素醋酸锌凝胶和软膏治疗寻常型痤疮的疗效和安全性。方法：采用随机、双盲、平行对照试验。以1%克林霉素磷酸酯凝胶为对照,设红霉素醋酸锌凝胶和红霉素醋酸锌软膏2个试验组,用药后6 wk评价疗效,并观察不良反应。结果：共入选60例病人。58例完成试验,对照组、软膏组和凝胶组各有19例,20例和19例。治疗6 wk后3组病人的黑头粉刺、白头粉刺、炎性丘疹和脓疱数较治疗前均有显著下降(P＜0.01),3组间变化无差异(P＞0.05)。对照组、软膏组和凝胶组有效率分别为58%,65%和63%,各组间疗效比较差异无显著意义(P＞0.05)。3组皮肤局部不良反应发生分别为3例,1例和1例,无全身不良反应发生。结论：红霉素醋酸锌凝胶和软膏是安全有效的治疗寻常型痤疮的外用药。     

克痤隐酮凝胶治疗寻常痤疮疗效观察

目的探讨克痤隐酮凝胶治疗寻常痤疮的临床疗效。方法92例随机分为两组，治疗组予克痤隐酮凝胶外用，对照组予5％过氧苯甲酰凝胶外用。结果两组患者炎性皮损数目较非炎性皮损数目明显减少；克痤隐酮凝胶治疗寻常痤疮的有效率为83．33％，5％过氧苯甲酰凝胶治疗寻常痤疮的有效率为84．09％，两组有效率差异无显著性（P〉0．05）。结论克痤隐酮凝胶治疗寻常痤疮和5％过氧苯甲酰凝胶同样有效。     

维胺脂及复方硫黄洗剂治疗寻常痤疮疗效观察

我院自1995年以来采用维胺脂及复方硫黄洗剂治疗寻常痤疮252例,取得良好效果,现报告如下:1 资料与方法1．1 临床资料:312例中．男129例,女183例,年龄18~35岁,平均23.5岁。病程2月~8年,平均2.8年。皮疹类型:黑头粉刺型84例,丘疹脓疱型151例,结节囊肿型77例。根据发病程度按Pillsbury分类法:Ⅰ°50例,Ⅱ°148例,Ⅲ°86例,     

替硝唑螺内酯乳膏治疗寻常痤疮62例

目的观察替硝唑螺内酯乳膏治疗寻常痤疮的临床疗效。方法将寻常痤疮患者94例分为两组,其中治疗组62例予替硝唑螺内酯乳膏,对照组32例予夫西地酸乳膏,局部外搽,每日2次,4周为1个疗程。结果治疗组总有效率91.94%,总显效率85.48%;对照组总有效率75.00%,总显效率37.50%。经统计学处理,治疗组疗效明显优于对照组（P〈0.05）。结论替硝唑螺内酯乳膏治疗寻常痤疮疗效确切,对痤疮患者炎症性皮损如丘疹、脓疱的消除尤为有效。     

复方硫磺洗剂与红霉素联合治疗痤疮的疗效观察

目的:观察复方硫磺洗剂与红霉素联合用药治疗痤疮的疗效。方法:100例痤疮患者按严重程度分为轻、中、重度,按双盲设计要求,随机分为2组,每组各50例:对照组给予外用复方硫磺洗剂,该洗剂由本院制剂室配制,处方配制按照《中国医院制剂规范》规定执行;治疗组给予外用复方硫磺洗剂联合红霉素,所用药物为每100mL复方硫磺洗剂加入6支红霉素无菌粉末(共1.5g)。4周为1疗程,每周复诊或随访1次,并观察记录患者粉刺、炎性丘疹、脓包和结节囊肿个数。结果:复方硫磺洗剂与红霉素联合治疗痤疮的总有效率(76%)明显高于对照组(38%),2组比较有显著性差异(P<0.05),且在治疗过程中不良反应发生率较低。结论:复方硫磺洗剂联合红霉素治疗痤疮疗效较好,副作用较少,且用药方便。     

复合维生素E,C,B组合物面膜治疗寻常痤疮117例的疗效和安全性(英文)

目的:了解维生素E,C,B组合物面膜治疗寻常痤疮的疗效及安全性。方法:117例13a以上、痤疮严重程度分级在2级以上且主要表现于脸部的病人,予维生素E,C,B组合物面膜治疗,每日1次,共8wk。观察治疗前后痤疮数量及性质,包括粉刺、丘疹、脓疱及囊肿之数目,并评估整体疗效。结果:治疗后,粉刺、丘疹、脓疱及囊肿数目下降了13±s13,10±12,5±7及3±3,均P<0.01。7例(6.0%)病人症状完全改善,44例(37.6%)中度改善,56例(47.9%)轻度改善,10例(8.6%)无改善。59例(50.4%)病人无红肿、搔痒、灼热及脱皮等现象发生。结论:维生素E,C,B组合物面膜治疗痤疮有效,超过半数的受试者无不良反应发生,可作为传统治疗寻常痤疮药物的替代。     

Clinical experience with 0.025% retinoic acid solution (‘Retin-A’) in the topical treatment of acne

Summary

Fifty-seven patients suffering from acne vulgaris were treated for 12 weeks with 0.025% wjw retinoic acid lotion. At the end of this period, 55% of patients showed good to excellent clinical improvement, with 95% showing some overall benefit. The early lesions (comedones, papules and pustules) showed a marked reduction in numbers. Irritant side-effects were slight and did not present a problem.     

痤炎灵1号治疗寻常性痤疮103例

目的:观察自制痤炎灵1号治疗寻常性痤疮的疗效和安全性.方法:寻常性痤疮103例,给予痤炎灵1号每天早晚洗脸后涂搽患处1次,疗程4周.观察粉刺、炎性丘疹、脓疱和结节等损害的变化以及不良反应的发生情况.结果:基本痊愈28例(27.2%),显效61例(59.2%),有效11例(10.7%),总有效率86.4%.无明显不良反应.结论:痤炎灵1号治疗寻常性痤疮安全,有效.     

阿达帕林凝胶联合甘草锌颗粒治疗寻常性痤疮42例疗效观察

目的:探讨阿达帕林凝胶联合甘草锌颗粒对寻常性痤疮患者皮损数目的影响.方法:回顾性分析2017年3月至2020年3月于焦作市第二人民医院就诊的85例寻常性痤疮患者作为研究对象,42例采用阿达帕林凝胶联合甘草锌颗粒治疗的患者资料作为观察组,同期43例采用甘草锌颗粒治疗的患者资料作为对照组,均治疗2个月.比较两组临床疗效、皮...     

氯霉素地塞米松搽剂的制备及其临床应用

目的介绍氯霉素地塞米松搽剂的制备,及其在轻中度寻常痤疮中的疗效。方法制备氯霉素地塞米松搽剂,并对其进行质量控制。分析其与氯霉素搽剂在轻中度寻常痤疮治疗过程中的临床疗效。结果本品制作简便,质量符合《中国药典》要求,与氯霉素搽剂比较,本品对轻中度寻常痤疮的治疗疗效更佳、不良反应更少。结论本品制备工艺可靠,质量可控,对轻中毒寻常痤疮的治疗疗效佳,不良反应少,是寻常痤疮治疗的好选择。     

A multicenter clinical evaluation of the treatment of mild to moderate inflammatory acne vulgaris of the face with visible blue light in comparison to topical 1% clindamycin antibiotic solution

BACKGROUND: Blue light sources have been shown to be effective in the treatment of mild to moderate inflammatory acne vulgaris lesions. OBJECTIVE: We evaluated the safety and efficacy of a new blue light source in the treatment of mild to moderate inflammatory acne vulgaris in comparison to topical 1% clindamycin solution. RESULTS: Blue light therapy reduced inflammatory acne vulgaris lesions by an average of 34%, as compared to 14% for topical 1% clindamycin solution. CONCLUSIONS: The blue light source presented in this report is a safe and effective treatment option available to our patients with mild to moderate inflammatory acne lesions.     

Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice

Efficacy and tolerability of a gel preparation with 0.025% tretinoin and 4% erythromycin in acne vulgaris was evaluated in an open multicentre study. A total of 1337 patients of either sex, aged 8 to 68 years, were enrolled in the study; 13 had to be excluded from analysis. Some 499 patients had received former acne treatment; this was described as non-efficient or poorly efficient in 90% of the patients. The treatment period lasted up to 14 weeks. Efficacy was determined by counting the acne lesions (comedones, papules and pustules) before drug administration and every second week during the treatment period. Lesions had diminished after 2 weeks in about 35% of the patients. At the end of the treatment period, comedones were eliminated in 47.0% and improved in another 41.4%. Papules were eliminated and improved in 58.2% and 32.6%, pustules in 74.3% and 18.3% respectively. Side-effects (erythema, burning, pruritus, scaling and dryness of the skin) occurred in 203 patients (15.3%). Treatment was stopped in 25 subjects (1.9%) due to intolerance reactions. The results of the present study thus confirm the high efficacy and tolerability of the fixed combination observed previously in more selected patients. The fixed combination of tretinoin and erythromycin makes retinoic acid treatment possible even by a general practitioner.     

异维A酸红霉素凝胶治疗寻常痤疮的多中心随机平行对照临床试验

目的:评价异维A酸红霉素凝胶治疗轻、中度寻常痤疮的疗效和安全性。方法:采用多中心随机、盲法、阳性药平行对照试验设计。试验组予异维A酸红霉素凝胶,对照组予维A酸乳膏。均为每晚一次,涂抹在全部患处,疗程为8 wk,观察疗效及不良反应。结果:共入组240例病人,进入疗效分析226例,其中试验组111例,对照组115例。治疗后,试验组与对照组综合疗效有效率分别为87.4% (97/111)和81.7%(70/115),2组综合疗效无显著差异(P>0.05);不良反应发生率分别为10.2%和7.6%(P>0.05)。结论:异维A酸红霉素凝胶治疗轻、中度寻常痤疮安全有效。     

Efficacy and safety of 2% supramolecular salicylic acid compared with 5% benzoyl peroxide/0.1% adapalene in the acne treatment: a randomized,split-face,open-label,single-center study

Background: Topical drugs for mild to moderate acne include adapalene (ADA) and benzoyl peroxide(BPO). Supramolecular salicylic acid (SSA), a modified SA preparation, is considered as a new effective therapeutic scheme.

Objectives: To compare the safety and efficacy of 2% supramolecular SA (2% SSA) with 0.01% adapalene plus 5% benzoyl peroxide (5%BPO +0.1%ADA) for treatment of facial acne.

Materials and methods: This was an open-label, split face, randomized and single-centre clinical trial. Subjects with mild to moderate acne were enrolled. Two percent SSA cream were randomly applied on one side of the face while 5%BPO +0.1%ADA gel was applied on the opposite side for 28?days. The numbers of acne lesions, along with side effects of the targeted area were evaluated by the investigators at day 0, day 14, and day 28. Skin water content, TEWL and skin lightening indexes were measured at the same time.

Results: A total of 31 of acne patients completed the trial. Dates showed that 2% SSA had similar effects to 5%BPO +0.1%ADA in reducing papules/pustules (47.9% vs. 49.8%), non-inflammatory lesions (43.1% vs. 42.7%) and total lesions (44.1% vs. 45.6%; all p?>?0.05) at day 28. The skin barrier (skin hydration value and TEWL value), skin brightness (L* value) and erythema (a* values) indicators showed no statistical differences in the left and right sides of the face (p?>?0.05).

Conclusion: This study demonstrated that 2% SSA has a similar efficacy with 5%BPO +0.1%ADA in mild to moderate acne treatment. This might be a useful pilot study that could be used to support further larger clinical trials.